XmAb 808
Alternative Names: B7-H3 x CD28 - Xencor; XmAb-808Latest Information Update: 23 Feb 2026
At a glance
- Originator Xencor
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 23 Feb 2026 Phase I development is ongoing in USA (IV) (Xencor pipeline, February 2026)
- 23 Feb 2026 Xencor plans a clinical trial for Solid tumours (Combination therapy) (Xencor pipeline, February 2026).
- 28 Dec 2025 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV)